On 7 January 2019 NHS England published its long-term plan for the NHS
NASS knows that not everyone in the UK gets the same standard of care for their axial SpA (AS) – that’s why we've launched our new campaign Every Patient, Every Time.
Meet the winners of our 2018 Patients' Choice Awards. This is what excellence looks like.
Izana Bioscience, a new UK based pharmaceutical company, is running a phase 2 clinical trial for 42 patients across 10 centres in the UK for its new drug, Namilumab.
NASS Stoke on Trent need your support to help to save their hydrotherapy pool.
Flu can be more severe in certain people, including anyone aged 65 and over and people with weakened immune systems. This would include people on biologic therapies like anti TNF or anti IL 17A, on regular steroids or taking DMARDs such as methotrexate
The patent for adalimumab, brand name Humira® has expired. New biosimilar versions of the drug are now available.
NASS CEO Dr Dale Webb targets the 8.5 year delay to diagnosis during Bone and Joint Week 2018
We're delighted to return to Northern Ireland on 27 October, bringing people with axial SpA (AS) together
NASS has been asked a few times recently about a no-deal Brexit and the impact that this may have on the supply of medicines to the UK.